Data / Drug companies / Vitruvias Therapeutics
Vitruvias Therapeutics: 30 products in the FDA NDC directory, labeler code 69680
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Vitruvias Therapeutics (labeler code 69680) lists 30 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 30 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 20, 2025.
The request: Watch Vitruvias Therapeutics (FDA labeler code 69680): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 69680
- Products in commercial distribution
- 30
- Packages
- 44
- Finished drugs by generic name
- 10
- Prescription products
- 30
- Over the counter products
- 0
- Flagged as original packager
- 30 of 30 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- December 3, 2018
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 25 | 83.3% |
| Other unapproved drugs | 5 | 16.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 30 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Thyroid | 5 | 3 |
| Topiramate | 5 | 56 |
| Memantine hydrochloride | 4 | 36 |
| Propafenone | 3 | 1 |
| Cyanocobalamin | 3 | 25 |
| Aminocaproic acid | 3 | 23 |
| Pramipexole dihydrochloride | 2 | 23 |
| Memantine hydrochloride and donepezil hydrochloride | 2 | 2 |
| Bupropion hydrochloride | 2 | 67 |
| Icosapent ethyl | 1 | 21 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, extended release | 14 | 46.7% |
| Tablet | 7 | 23.3% |
| Tablet, extended release | 4 | 13.3% |
| Injection, solution | 3 | 10% |
| Capsule | 1 | 3.3% |
| Solution | 1 | 3.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| N-methyl-D-aspartate Receptor Antagonist | 6 |
| Antiarrhythmic | 3 |
| Vitamin B12 | 3 |
| Antifibrinolytic Agent | 3 |
| Nonergot Dopamine Agonist | 2 |
| Cholinesterase Inhibitor | 2 |
| Aminoketone | 2 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Icosapent Ethyl | 69680-186 | Capsule | Generic drugs (ANDA) | October 20, 2025 |
| Memantine hydrochloride and donepezil hydrochloride | 69680-185 | Capsule, extended release | Generic drugs (ANDA) | July 16, 2025 |
| Memantine hydrochloride and donepezil hydrochloride | 69680-183 | Capsule, extended release | Generic drugs (ANDA) | July 16, 2025 |
| Topiramate | 69680-181 | Capsule, extended release | Generic drugs (ANDA) | April 7, 2025 |
| Topiramate | 69680-180 | Capsule, extended release | Generic drugs (ANDA) | April 7, 2025 |
| Topiramate | 69680-179 | Capsule, extended release | Generic drugs (ANDA) | April 7, 2025 |
| Topiramate | 69680-178 | Capsule, extended release | Generic drugs (ANDA) | April 7, 2025 |
| Topiramate | 69680-177 | Capsule, extended release | Generic drugs (ANDA) | April 7, 2025 |
| Thyroid | 69680-169 | Tablet | Other unapproved drugs | November 22, 2024 |
| Thyroid | 69680-168 | Tablet | Other unapproved drugs | November 22, 2024 |
| Thyroid | 69680-167 | Tablet | Other unapproved drugs | November 22, 2024 |
| Thyroid | 69680-166 | Tablet | Other unapproved drugs | November 22, 2024 |
| Thyroid | 69680-165 | Tablet | Other unapproved drugs | November 22, 2024 |
| Aminocaproic Acid | 69680-114 | Solution | Generic drugs (ANDA) | July 19, 2024 |
| Memantine Hydrochloride | 69680-163 | Capsule, extended release | Generic drugs (ANDA) | February 19, 2024 |
| Memantine Hydrochloride | 69680-164 | Capsule, extended release | Generic drugs (ANDA) | December 15, 2023 |
| Memantine Hydrochloride | 69680-162 | Capsule, extended release | Generic drugs (ANDA) | December 15, 2023 |
| Memantine Hydrochloride | 69680-161 | Capsule, extended release | Generic drugs (ANDA) | December 15, 2023 |
| Bupropion hydrochloride (XL) | 69680-158 | Tablet, extended release | Generic drugs (ANDA) | April 10, 2023 |
| Bupropion hydrochloride (XL) | 69680-157 | Tablet, extended release | Generic drugs (ANDA) | April 10, 2023 |
| Pramipexole Dihydrochloride | 69680-146 | Tablet, extended release | Generic drugs (ANDA) | August 27, 2021 |
| Pramipexole Dihydrochloride Extended-Release | 69680-145 | Tablet, extended release | Generic drugs (ANDA) | August 27, 2021 |
| Cyanocobalamin | 69680-121 | Injection, solution | Generic drugs (ANDA) | February 12, 2020 |
| Propafenone Hydrochloride | 69680-132 | Capsule, extended release | Generic drugs (ANDA) | January 28, 2019 |
| Propafenone Hydrochloride | 69680-131 | Capsule, extended release | Generic drugs (ANDA) | January 28, 2019 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.